Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection

Huang Liang; Peiyan Zheng; Qian Wang; Yijun Deng; Dan Liang; Haisu Yi; Yuanyi Cheng; Xinwei Zhao; Jing Ma; Yidong Yang; Peiyu Hu; Pingqian Zheng; Yudi Zhang; Shuangshuang Huang; Xiancheng Lin; Changwen Ke; Xuefeng Niu; Baoqing Sun; Ling Chen

doi:10.1080/22221751.2022.2076613

Emerging Microbes and Infections (Dec 2022)

Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection

Huang Liang,
Peiyan Zheng,
Qian Wang,
Yijun Deng,
Dan Liang,
Haisu Yi,
Yuanyi Cheng,
Xinwei Zhao,
Jing Ma,
Yidong Yang,
Peiyu Hu,
Pingqian Zheng,
Yudi Zhang,
Shuangshuang Huang,
Xiancheng Lin,
Changwen Ke,
Xuefeng Niu,
Baoqing Sun,
Ling Chen

Affiliations

Huang Liang: State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China
Peiyan Zheng: State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China
Qian Wang: State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China
Yijun Deng: State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China
Dan Liang: Guangdong Provincial Centre for Diseases Control and Prevention, Guangzhou, People’s Republic of China
Haisu Yi: State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China
Yuanyi Cheng: State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China
Xinwei Zhao: Guangdong Laboratory of Computational Biomedicine, Guangdong-Hong Kong-Macau Joint Laboratory of Respiratory Infectious Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
Jing Ma: State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China
Yidong Yang: State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China
Peiyu Hu: Guangzhou Laboratory, Guangzhou, People's Republic of China
Pingqian Zheng: Guangzhou Laboratory, Guangzhou, People's Republic of China
Yudi Zhang: Guangdong Laboratory of Computational Biomedicine, Guangdong-Hong Kong-Macau Joint Laboratory of Respiratory Infectious Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
Shuangshuang Huang: State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China
Xiancheng Lin: State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China
Changwen Ke: Guangdong Provincial Centre for Diseases Control and Prevention, Guangzhou, People’s Republic of China
Xuefeng Niu: State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China
Baoqing Sun: State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China
Ling Chen: State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China

DOI: https://doi.org/10.1080/22221751.2022.2076613
Journal volume & issue: Vol. 11, no. 1
pp. 1500 – 1507

Abstract

Read online

In vaccinees who were infected with SARS-CoV in 2003, we observed greater antibody responses against spike and nucleoprotein of both SARS-CoV-2 and SARS-CoV after a single dosage of inactivated SARS-CoV-2 vaccine. After receiving the second vaccination, antibodies against RBD of SARS-CoV-2 Wuhan, Beta, Delta, and recently emerged Omicron are significantly higher in SARS-CoV experienced vaccinees than in SARS-CoV naïve vaccinees. Neutralizing activities measured by authentic viruses and pseudoviruses of SARS-CoV, SARS-CoV-2 Wuhan, Beta, and Delta are greater in SARS-CoV experienced vaccinees. In contrast, only weak neutralizing activities against SARS-CoV-2 and variants were detected in SARS-CoV naïve vaccinees. By 6 months after the second vaccination, neutralizing activities were maintained at a relatively higher level in SARS-CoV experienced vaccinees but were undetectable in SARS-CoV naïve vaccinees. These findings suggested a great possibility of developing a universal vaccine by heterologous vaccination using spike antigens from different SARS-related coronaviruses.

Published in Emerging Microbes and Infections

ISSN: 2222-1751 (Online)
Publisher: Taylor & Francis Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Infectious and parasitic diseases; Science: Microbiology
Website: https://www.tandfonline.com/journals/temi

About the journal

Abstract

Keywords